P002 Surgical Resection Improves the Survival of NSCLC Patients With Pleural Metastasis Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.027
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

OA07.05 Local Ablative Therapy Improves Survival in Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated With EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.15-30 Survival of Patients With Advanced NSCLC Treated With First-Generation EGFR-TKIs at a Cancer Hospital in Thailand, 2011-2016

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-65 First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients With EGFR-Mutant Metastatic NSCLC Receiving TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2018English

P2.15-26 Rates and Economic Burden of Adverse Events in Patients With Metastatic NSCLC Treated With EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study

Integrative Cancer Therapies
OncologyAlternative MedicineComplementary
2019English

P1.13-26 First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant NSCLC Patients With Oligoprogressive Disease

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy